|
|
| (12 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atorvastatin#Contraindications]] |
| {{Atorvastatin}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| [[Atherosclerosis]] is a chronic process and discontinuation of lipid lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of [[primary hypercholesterolemia]]. | |
| | |
| [[Cholesterol]] and other products of [[cholesterol biosynthesis]] are essential components for fetal development (including synthesis of steroids and cell membranes). Since [[HMG-CoA reductase inhibitor]]s decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, [[HMG-CoA reductase inhibitor]]s are contraindicated during pregnancy and in nursing mothers.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIPITOR (ATORVASTATIN CALCIUM) TABLET, FILM COATED [PARKE-DAVIS DIV OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6e131fe-e7df-4876-83f7-9156fc4e8228#nlm34089-3 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| '''Atorvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards.'''
| |
| | |
| '''If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.'''
| |
| | |
| ==Contraindications of Atorvastatin==
| |
| | |
| ===Active liver disease or unexplained persistent elevations of serum transaminases===
| |
| | |
| ===Hypersensitivity to any component of this medication===
| |
| | |
| ===Pregnancy and Lactation===
| |
| | |
| <br>
| |
| <br>
| |
| | |
| {{FDA}}
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| | |
| | |
| [[Category:Drugs]]
| |